LAURA BEAUFFORD: Open Payments
NPI 1619563343 · AUSTIN, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$853 in 43 payments from 12 companies in 2025. Trend: 2023 $104 · 2024 $320 · 2025 $853
Food & beverage: $853
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 15 | $244 |
| Otsuka America Pharmaceutical, Inc. | 9 | $147 |
| Axsome Therapeutics, Inc. | 2 | $141 |
| Vanda Pharmaceuticals Inc. | 4 | $89 |
| Janssen Pharmaceuticals, Inc | 2 | $51 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $46 |
| E.R. Squibb & Sons, L.L.C. | 2 | $33 |
| Corium, LLC | 3 | $32 |
| Supernus Pharmaceuticals, Inc. | 1 | $20 |
| Teva Pharmaceuticals USA, Inc. | 1 | $18 |
Products named: VRAYLAR, REXULTI, Auvelity, FANAPT, SPRAVATO, CAPLYTA, COBENFY, Azstarys.
Industry payments across TX — which companies pay providers there.
